Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

You may be eligible if

• Histologically confirmed solid tumor at original diagnosis that has failed standard therapy or for which no standard therapy exists
• * Patients must have a disease for which there is no known curative potential
• Patients must meet the following criteria for bone marrow function:
• * Status post stem cell transplantation (SCT)
• * Absolute neutrophil count at least 1,500/mm\^3
• * Platelet count at least 100,000/mm\^3 (transfusion independent)
• * Hemoglobin at least 8.0 g/dL (RBC transfusions allowed)
• No lymphomas
• No CNS tumors or known metastatic disease to the brain or spinal cord
• Performance status - Karnofsky 50-100% (age 11 to 21)
• Performance status - Lansky 50-100% (age 1 to 10)
• At least 8 weeks
• See Disease Characteristics
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• ALT no greater than 3 times ULN
• No significant hepatic dysfunction
• Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
• Creatinine, based on age, as follows:
• * Age 1 to 5: no greater than 0.8 mg/dL
• * Age 6 to 10: no greater than 1.0 mg/dL
• * Age 11 to 15: no greater than 1.2 mg/dL
• * Age 16 to 21: no greater than 1.5 mg/dL
• No significant renal dysfunction
• Shortening fraction at least 28% by echocardiogram
• Ejection fraction at least 45% by MUGA
• No significant pulmonary dysfunction
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No serious uncontrolled infections
• No other end-organ dysfunction that would preclude study entry
• No other clinically significant systemic illness
• See Disease Characteristics
• Recovered from prior immunotherapy
• At least 1 week since prior growth factors or other biologic agents
• At least 6 months since prior autologous SCT
• At least 6 months since prior allogeneic bone marrow transplantation and recovered with no evidence of graft-versus-host disease
• No concurrent immunomodulating agents
• No concurrent prophylactic growth factors during the first course of the study
• No concurrent immunotherapy or other biologic therapy
• Recovered from prior chemotherapy
• At least 2 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
• No prior life-time cumulative doxorubicin dose of more than 450 mg/m\^2 or equivalent
• No other concurrent chemotherapy
• Concurrent chronic steroids allowed
• Recovered from prior radiotherapy
• More than 2 weeks since prior localized palliative radiotherapy (small port)
• More than 6 months since prior substantial radiotherapy to bone marrow (craniospinal radiotherapy, total body irradiation, or hemi-pelvic radiotherapy)
• No concurrent radiotherapy
• Concurrent chronic medications (e.g., narcotics or antiepileptics) allowed
• No other concurrent investigational agents
• No other concurrent cancer therapy